KLP Kapitalforvaltning AS acquired a new position in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) in the fourth quarter, ...

Cas9, scientists reconstitute live African swine fever virus from synthetic genomes, accelerating vaccine development for ...

Guidelines created by a multi-disciplinary panel of specialists focus on implementation of novel treatments and technologies for which level 1 evidence is lacking.

a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression ...

Horizontal gene transfer (HGT) is the movement of genetic material from one organism to another. In this article, we will ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer On ...

Imunon is initiating sites for the trial and collaborating with investigators to commence participant enrolment.

Toxicity related to the systematic delivery of IL-12, a well-known and widely researched anti-tumor cytokine, has limited its ...

IDEAYA Biosciences, Inc.’s IDYA share price has surged by 10.70%, which has investors questioning if this is right time to sell.

FDA approvals exist for monotherapy with rucaparib for those with BRCA1 or BRCA2 mutated mCRPC, while olaparib has a broader label for patients with pathogenic mutations in any one of 14 homologous ...

IMUNON (IMNN) announced that the U.S. Food and Drug Administration is aligned with the protocol for the Phase 3 pivotal trial, called OVATION ...